Back to search results

AMAZE 9: Zenagamtide Tablets for Excess Body Weight

This study, called AMAZE 9, is investigating if zenagamtide tablets are a safe and effective way to help people with excess body weight lose weight. You would take an oral tablet once a day. Participants will either receive zenagamtide or a placebo (a tablet with no active medicine). Which treatment you receive is decided by chance. The main goal is to see how much body weight changes over 76 weeks. To join, you must be 18 years or older and have a glycated hemoglobin (HbA1c) level less than 6.5%. The study is currently recruiting about 950 participants.

Study design
This is an interventional study where participants are randomly assigned to receive either zenagamtide or a placebo. It aims to enroll about 950 participants.
What's involved
You would take an oral tablet once a day. The primary endpoint for measuring body weight change is from baseline (week 0) to week 76.
Compensation
Not stated in the trial record.
Follow-up
The study measures body weight changes from the start of the study (week 0) up to week 76.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720271

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~950 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:zenagamtidePlacebo

At a glance

Recruiting sites
0 of 42 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in body weight
Measured over From baseline (week 0) to (week 76)

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

42 sites across 18 states
Florida8
North Carolina5
Illinois4
South Carolina4
Alabama3
California3
Virginia3
Texas2

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth).
Age 18 and older (both inclusive) at time of signing the informed consent.

Exclusion

Glycated haemoglobin (HbA1c) more than or equal to (≥) 6.5% \[48 millimoles per mole (mmol/mol)\] as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening.

What this trial measures

  • Relative change in body weightFrom baseline (week 0) to (week 76)

    Measured as percentage (%) change in body weight.